Clinical trial Archives

News and Trends 31 Oct 2022

First patient enrolled and dosed on expansion phase of cancer treatment trial

The first patient in an expansion phase of a trial looking at cancer drug Modi-1 has been enrolled and dosed. Scancell Holdings plc, the developer of immunotherapies for the treatment of cancer and infectious disease made the announcement today (October 31). The expansion phase is part of the monotherapy arms of the phase 1 clinical […]

October 31, 2022 - 3 minutesmins - By Liza Laws

AKT inhibitor ipatasertib shows signs of effectiveness in patient trial

News and Trends 28 Oct 2022

AKT inhibitor shows signs of effectiveness in patient trial

In a trial matching new treatments to cancer patients based on the genetic make-up of their tumors, 22% of the patients treated with the AKT inhibitor drug ipatasertib had their tumors shrink. This included patients with breast cancer and endometrial cancer as well as two rarer forms – anal and salivary gland. In the majority […]

October 28, 2022 - 3 minutesmins - By Jim Cornall

More News! 26 Oct 2022

Study shows ability to develop and apply targeted treatment in head and neck cancers

A joint study looked at the development identification of specific markers to improve risk assessment of patients with difficult to treat head and neck tumors. Malignant tumors in these areas are very heterogeneous and have a lack of prognostic markers – a significant impediment to personalized treatment. The joint study by MedUni Vienna and the […]

October 26, 2022 - 3 minutesmins - By Liza Laws

News and Trends 26 Oct 2022

First patient dosed in trial to assess predictive performance of immuno-oncology therapy

The first patient has been dosed at the Macquarie University Hospital in Sydney as part of a clinical trial to evaluate whether a drug can predict patient response to immuno-oncology therapy targeting a number of solid tumor types. ImaginAb Inc. is a biotech company developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent and next generation […]

October 26, 2022 - 3 minutesmins - By Liza Laws

News and Trends 26 Oct 2022

Inotrem study for the treatment of critically ill COVID-19 patients meets endpoints

Inotrem has announced positive results for ESSENTIAL, its phase II clinical trial in COVID-19 patients hospitalized in critical care units and experiencing acute respiratory distress. The French clinical stage biotech company specializes in immunotherapies for acute and chronic inflammatory syndromes. The announcement was made at the European Society of Intensive Care Medicine’s Annual Congress, held […]

October 26, 2022 - 3 minutesmins - By Jim Cornall

More News! 24 Oct 2022

Sensorion gets go-ahead from France for trial of drug to prevent hearing loss

Biotech company, Sensorion, today (October 24) announced that the initiation of a proof of concept (PoC) clinical trial of SENS-401 (Arazasetron) in patients with Cisplatin-Induced Ototoxicity (CIO) has been approved by the regulatory authorities in France. Cisplatin and other platinum-based compounds are essential chemotherapeutic agents for many cancers. A serious side effect of these therapies […]

October 24, 2022 - 3 minutesmins - By Liza Laws

News and Trends 19 Oct 2022

Domain Therapeutics to start clinical trials of solid tumor treatment

Domain Therapeutics says its immuno-oncology candidate has been cleared in Belgium and France, leading to a phase I clinical trial. It has cleared its clinical trial applications with the ANSM (Agence Nationale de Sécurité du Médicament et des produits de santé) in France and the AFMPS (Agence Fédérale des Médicaments et des Produits de Santé) […]

October 19, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 18 Oct 2022

Progress of COPD drug boosted by debt financing of up to $150M

Verona Pharma plc has today (October 17) announced that it has entered into a debt financing facility providing access of up to $150 million from Oxford Finance LLC. The non-dilutive capital provides further financial flexibility and support for commercialization activities for ensifentrine, the company’s product candidate, which recently reported positive phase 3 data in the […]

October 18, 2022 - 2 minutesmins - By Liza Laws

More News! 17 Oct 2022

Clinical trial of treatment for advanced solid tumors approved

A clinical trial of a drug to treat advanced solid tumors has been approved by the National Medical Products Administration. China-based Akeso Inc., made the announcement on Sunday (October 16) about a phase 1b/2 clinical trial of its in-house developed Ivonescimab (PD-1/VEGF bi-specific AK112) combined with Drebuxelimab (CD73, AK119). AK112 is the first PD-1/VEGF bi-specific […]

October 17, 2022 - 2 minutesmins - By Liza Laws

News and Trends 17 Oct 2022

More positive news announced for Verona’s COPD treatment

Clinical-stage biopharmaceutical company, Verona, has announced more positive news from its phase 3 ENHANCE-2 clinical trial of ensifentrine that treats chronic obstructive pulmonary disease (COPD). The company focuses on respiratory diseases, and made the announcement today (October 14) about the positive analyses demonstrating how ensifentrine reduced exacerbation rates across subgroups in the trial. Ensifentrine is […]

October 17, 2022 - 3 minutesmins - By Liza Laws

News and Trends 13 Oct 2022

Plan launched to improve diversity of clinical trials

Help to improve the equity of clinical trials by providing site-level participant demographic data including race, sex, age and ethnicity has been revealed. Medidata, a Dassault Systèmes company, has launched the intelligent trials diversity module. The new module will help sponsors and clinical research organizations (CROs) benchmark the diversity of their trials and identify sites […]

October 13, 2022 - 3 minutesmins - By Liza Laws

News and Trends 13 Oct 2022

Merck contributing to Jacobio Pharma colorectal cancer clinical trial

Jacobio announced it has entered into a clinical trial collaboration agreement with Merck on a clinical study of combination therapy between Jacobio’s KRAS G12C inhibitor JAB-21822 and Merck’s epidermal growth factor receptor (EGFR) inhibitor Erbitux (cetuximab). This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated […]

October 13, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Clinical trial

First patient enrolled and dosed on expansion phase of cancer treatment trial

AKT inhibitor shows signs of effectiveness in patient trial

Study shows ability to develop and apply targeted treatment in head and neck cancers

First patient dosed in trial to assess predictive performance of immuno-oncology therapy

Inotrem study for the treatment of critically ill COVID-19 patients meets endpoints

Sensorion gets go-ahead from France for trial of drug to prevent hearing loss

Domain Therapeutics to start clinical trials of solid tumor treatment

Progress of COPD drug boosted by debt financing of up to $150M

Clinical trial of treatment for advanced solid tumors approved

More positive news announced for Verona’s COPD treatment

Plan launched to improve diversity of clinical trials

Merck contributing to Jacobio Pharma colorectal cancer clinical trial

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!